On October 12, 2022, the FDA confirmed what many patients with attention-deficit / hyperactivity disorder (ADHD) already knew: There was a shortage of the immediate-release formulation of amphetamine mixed salts commonly known by the brand name Adderall. The implications of this announcement have rippled across the United States, affecting scores of patients reliant on the…
Why is there an Adderall shortage? And what does it mean for patients?
A widespread shortage of Adderall (amphetamine and dextroamphetamine) in the latter part of 2022 left millions of patients looking for an alternative treatment strategy or dealing with withdrawal symptoms. A Sermo survey found that about half of 348 physicians had encountered patients dealing with the Adderall shortfall. Of the physicians surveyed, 82%, were concerned about the impact…
As Adderall shortage persists, many doctors are concerned
Supplies of the ADHD drug Adderall (amphetamine and dextroamphetamine) remain limited, forcing millions of patients to either search multiple pharmacies, ration their medication, seek alternatives or deal with withdrawal symptoms. Half of the physicians have directly witnessed the Adderall shortage in their practices, according to a recent Sermo survey of 348 physicians. Demand for Adderall is increasing.…
Adderall shortage could persist for remainder of 2022
Generic versions of the Takeda’s (NYSE:TAK) ADHD drug Adderall (amphetamine and dextroamphetamine) remain in short supply after some manufacturers predicted in September that supplies of the drug would stabilize. Experts remain that patients who have experienced trouble getting prescriptions filled switch to other similar amphetamine-based medications, according to The Washington Post. Teva (NYSE:TEVA) recently disclosed…